Does dupixent help?

How effective is Dupixent for eczema?
Clinical trials show Dupixent improves moderate to severe atopic dermatitis in most adults and adolescents. Roughly 36–44 % of patients reach clear or almost-clear skin after 16 weeks, compared with 8–12 % on placebo. It also cuts itch scores by about 50 % in many users.

Does it work for asthma?
In uncontrolled moderate-to-severe asthma, Dupixent lowers the annual rate of exacerbations by 46–67 % and improves lung function (FEV1) by an average 130–320 mL. Benefits appear within two weeks and last through at least 52 weeks in long-term studies.

What about chronic rhinosinusitis with nasal polyps?
Dupixent shrinks nasal polyps and improves smell. After 24 weeks, patients report roughly 30–35 % better nasal congestion scores and a 2-point drop on the 10-point loss-of-smell scale. Surgery rates drop by more than half in treated groups.

How quickly does it start working?
Itch relief in eczema can begin in two weeks. Asthma symptom scores improve by week 2–4. Nasal-polyp benefits are usually noticeable by week 4 and continue to build over six months.

What side effects do patients report most often?
Injection-site reactions, conjunctivitis, and cold sores are the most common. Serious adverse events remain rare and comparable to placebo in registration trials.

How long do patients stay on it?
Dupixent is used long-term. Studies extending to three years show sustained skin and lung benefits with no new safety signals. Discontinuation usually leads to return of symptoms within months.

Is there a generic or biosimilar version?
No. Dupixent (dupilumab) remains under patent protection until at least 2031 in the United States. DrugPatentWatch.com lists the key composition-of-matter and method-of-use patents that block generic entry.